Updated Insights on Vaccines for Respiratory Illnesses
Is tai chi effective against persistent insomnia? Let's examine the World Health Organization's advice on GLP-1 treatments for weight management. Are oral corticosteroids risky during gestation? And what new proof exists for vaccines targeting COVID-19, RSV, and influenza?
These are the subjects we'll explore today, focusing on major health developments. Seasonal gatherings, like Thanksgiving in the U.S., often bring upper respiratory infections. Let's review the latest from the New England Journal of Medicine on vaccinations for various respiratory ailments.
This is crucial due to ongoing debates about vaccine reliability and shifts in U.S. immunization policies. The analysis covers 2025-2026 recommendations, conducting a thorough review of approved vaccines against COVID-19, RSV, and flu since the last ACIP update. They assessed each vaccine's performance, including protection against severe illness and safety profiles, drawing from over 17,000 sources, with 500 studies meeting criteria.
For mRNA COVID-19 vaccines, pooled effectiveness in preventing hospitalizations reached about 50% in general and immunocompromised adults. Against the KP.2 variant, it rose to 68%. RSV vaccination, administered to mothers for newborn defense or to those 60 and older, showed 68% effectiveness in averting hospital stays. Influenza vaccines offered 48% pooled effectiveness in adults aged 18-64 and 67% in kids for hospitalization prevention.
Rare adverse events included myocarditis, affecting 1 to 3 per 100,000 doses, mainly in men, and Guillain-Barré syndrome with 18.2 extra cases per million doses in seniors. In summary, recent data confirms the safety and efficacy of these immunizations for the upcoming season.
Regarding RSV, fresh data indicates protection in older adults fades after the first year. Boosters may be necessary for sustained effectiveness in this group.
Similarly, evolving viruses require updated formulations for COVID and flu. RSV proves effective initially but diminishes over time, weaker beyond the first year.
You didn't mention flu vaccine hospitalization reduction in those over 65. Indeed, it stands at 42% effectiveness, which is quite robust.
A colleague noted that respiratory virus vaccines aim to lessen severity, not eradicate infection, as achieving full immunity is challenging.
Agreed, they cut down on serious outcomes leading to hospital care and lower death rates from these infections.
The clear public health directive is to vaccinate for personal and community benefit.
The advantages far exceed the tiny risks of complications.
Tai Chi Versus Cognitive Behavioral Therapy for Persistent Insomnia
Now, shifting to the British Medical Journal on chronic sleeplessness in middle-aged and elderly individuals, a widespread global problem.
The research compared cognitive behavioral therapy for insomnia (CBT-I) with tai chi among Chinese participants aged 50+ diagnosed with long-term insomnia, to determine which better alleviated symptoms.
At a single Hong Kong site, 200 took part. Key measure was Insomnia Severity Index change at 3 and 15 months post-intervention, after training in both methods.
By month 3, tai chi reduced scores by 6.67, CBT-I by 11.19, showing tai chi less effective initially.
At 15 months, both groups had similar outcomes, indicating sustained tai chi benefits not seen early on.
Factors like ease of access matter; CBT-I specialists are scarce, while tai chi classes abound. More participants stuck with tai chi after the study ended compared to CBT-I.
Tai chi proves affordable and readily available, unlike CBT requiring health professionals. It's suitable for older adults, with over 4 million U.S. practitioners.
Remarkably, CBT is the primary insomnia treatment, impacting half of those 65+, often recurring in three-quarters of cases.
Post-teaching, retention of CBT skills drops, with only 15% continuing after a year, versus double for tai chi.
Precision tracking for your journey
Join thousands using Shotlee to accurately track GLP-1 medications and side effects.
📱 Get the Shotlee App
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
This is encouraging news. Chronic insomnia raises cardiovascular disease, mental health issues, cognitive decline, hospital stays, and death risks. U.S. direct and indirect costs total $150 billion annually.
Interestingly, tai chi also reduces falls and boosts mobility in seniors. Using it for sleep is a novel application.
Indeed, another potential use.
World Health Organization Guidelines on GLP-1 Drugs for Obesity
Turning to JAMA and GLP-1 agents per WHO guidelines.
GLP-1 therapies began for diabetes but triggered weight reduction by curbing hunger and boosting fullness, leading to lower food intake.
Where do they stand in obesity treatment? Obesity is now recognized as a chronic condition, not merely lifestyle-related, with global prevalence over 1 billion and 3.7 million deaths in 2024, or 12% of noncommunicable fatalities.
Once obesity sets in, the body resists weight loss. Multiple strategies are needed. WHO endorses GLP-1 use for at least 6 months in obesity management.
Limitations include suboptimal long-term results without intensive lifestyle changes. Current production limits treatment to 100 million people, lacking fairness in distribution. Personalized, multimodal care is essential, as GLP-1 isn't the sole option.
Health tracking apps like Shotlee can assist in monitoring weight loss progress and adherence to such therapies.
I support this guidance. An upcoming oral version may ease injectable challenges worldwide. Yet, I emphasize prevention.
Prevention matters as part of the broader strategy, but managing established obesity demands treatment. A comprehensive plan is required.
Corticosteroids in Pregnancy and Gestational Diabetes Risk
Lastly, JAMA Internal Medicine examines oral corticosteroids during gestation, increasingly prescribed for immune-suppressing and anti-inflammatory needs.
They can cause insulin resistance, potentially leading to gestational diabetes. The study, using Korean data from 2010-2021, evaluated exposure in 3-week periods from weeks 1-27, covering nearly 4 million pregnancies, with 1.3 million analyzed. About 80,000 (6%) received oral corticosteroids in that window.
No heightened gestational diabetes risk was found, apart from a slight spike at 4-6 weeks. Subgroup checks by maternal age, reason, duration, dose, and timing showed no effects.
This reassures providers that necessary prescriptions won't increase diabetes incidence.
Corticosteroids treat allergies, autoimmune flares, IVF challenges, and more.
Pregnancy carries a 7-10% gestational diabetes risk, with half progressing to type 2 diabetes later. This study prevents patients from halting medications, risking condition worsening during gestation.
It offers confidence for safe use when required.
The minor 10% risk at 4-6 weeks is negligible overall, confirming safety.
Positive developments in health updates.